Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2013

View Archived Issues

MIR146A gene polymorphisms linked to atrial fibrillation prognosis

Presentation of the data from clinical trials of dulaglutide

Development of an antimalaria vaccine that targets disease transmission

Data from the clinical evaluation of a prophylactic therapy for patients with hemophilia B

Teva enters collaboration with Israeli academic institutions in neurodegenerative disease

North Carolina State University discloses new agents for bacterial infections

Researchers at Roche present novel tyrosine-protein kinase inhibitors

Teva and Lonza decide to discontinue joint venture in biosimilars

Roche synthesizes novel TAAR1 ligands

Candesartan is as effective as propranolol for preventing migraine

Invion begins phase II INV-102 trial

FDA approves Fetzima for major depressive disorder in adults

CHMP confirms Xeljanz recommendation

Thrombomodulin downregulated thrombin generation mediators/markers in sepsis-associated coagulopathy

New FSH receptor agonists disclosed by Merck KGaA for female infertility

AstraZeneca and Bristol-Myers Squibb resubmit NDA for dapagliflozin

Curis commences phase I study of CUDC-427 in advanced malignancies

Diazyme obtains 510(k) clearance from FDA to market its myoglobin assay

Jiangsu Hengrui Medicine synthesizes novel GPR40 agonists

Kyowa Hakko Kirin Korea begins patient recruitment in phase I/II study of BIW-8962 in lung cancer

Researchers at X-Rx/X-Chem report new tyrosine-protein kinase BTK inhibitors

Phase III orteronel study in metastatic castration-resistant prostate cancer unblinded

IND approved for oncolytic agent 3-bromopyruvate

InSite Vision reports topline results from DOUBle phase III study in blepharitis

Tesaro begins phase III trial of niraparib for treatment of ovarian cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...